CTLA4 and lung carcinoma: Previous studies have shown that the combination of MAP and an anti-CTLA4 antibody significantly enhances antitumor efficacy in CRC patients and lung cancer patients because MAP binds to SPOP through the ARG70 site, increases the protein expression level of SPOP, and thus induces PD-L1 ubiquitination.